Expert Interview
A Third Look: Examining the recent Top-line Data from Phase 1/2 Proof-of-Concept Study of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults.
Ticker(s): PCVX- Board Certified Internal Medicine
- Hospitalist since 2007
- Telemedicine Physician since 2011
- Sees approximately 15 patients per month with pneumococcal disease
- Reviewed the most recent topline data for the PCVX 24 valent vaccine
How would a new vaccine for pneumococcal disease change your preference for treatment?
Added By: max_adminOn a scale of 1-10 how excited are you regarding Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine Candidate?
Added By: max_adminWhat is the current standard care for someone with Pneumococcal disease?
Added By: max_adminDo you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
